In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...
FDA approves Poherdy, the first interchangeable biosimilar for pertuzumab (Perjeta), enhancing competition in HER2-positive ...
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.
April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She ...
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies. The competitive landscape for biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback